Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of keratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research:
https://doi.org/10.1159/000537979.